Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

roxifiban

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Thrombocytopenia is a relatively common side effect observed during glycoprotein (GP) IIb/IIIa antagonist therapy. With the oral… Expand
  • table I
  • table II
  • table III
  • figure 2
  • figure 4
Is this relevant?
2003
2003
BACKGROUND It has been expected that therapy with oral glycoprotein (GP) IIb/IIIa blockers including roxifiban will reduce… Expand
Is this relevant?
2003
2003
Introduction: Intravenous platelet glycoprotein (GP) IIb/IIIa receptor inhibitors have a significant beneficial impact on the… Expand
Is this relevant?
2003
2003
Roxifiban (DMP 754) is a glycoprotein (GP) IIb/IIIa antagonist. Following oral administration to humans, roxifiban is metabolized… Expand
Is this relevant?
2002
2002
Roxifiban, an experimental antithrombotic prodrug, exists as crystalline forms I and II. A quantitative solid-state nuclear… Expand
Is this relevant?
2002
2002
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state… Expand
Is this relevant?
2002
2002
This study was undertaken to compare the platelet binding characteristics and anti-platelet efficacy of a nonpeptide glycoprotein… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
In the present study, the in vitro efficacy of different platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on platelet… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2000
2000
Automation offers obvious advantages for the preparation of tablets prior to analysis by HPLC including unattended operation… Expand
Is this relevant?
1999
1999
Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?